 The
LABD ETF, or the S&P Biotech Bear -3X Direxion ETF, is an
exchange-traded fund that seeks to provide daily investment results
that correspond to three times the inverse of the daily performance of
the S&P Biotechnology Select Industry Index. The index is designed to
measure the performance of the biotechnology sub-industry based on the
Global Industry Classification Standard (GICS).
As of the most
recent report, the fund had total assets under management of
approximately $31 million and an expense ratio of 1.13%. The fund is
designed to be a leveraged ETF, which means that it is intended for
short-term trading and is not suitable for long-term investors.
The LABD ETF is designed for investors who seek to profit from
short-term declines in the biotechnology industry. The fund seeks to
provide three times the inverse daily return of the S&P Biotechnology
Select Industry Index, which means that if the index goes down by 1%,
the fund aims to go up by 3%. However, it's important to note that
leveraged ETFs are subject to significant risks and may experience
losses that exceed the original investment, particularly over longer
holding periods.
Overall, the LABD ETF may be appropriate for
investors who have a high tolerance for risk and who seek to make
short-term bets on the biotechnology industry. However, due to the
risks associated with leveraged ETFs, investors should carefully
consider their investment goals and risk tolerance before investing in
the fund.
|
